immunology

HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.

CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor.

Pirazolac (ZK-76604) is a novel non-steroidal anti-inflammatory agent for the study of rheumatoid arthritis.

INCB3619 is a selective and potent inhibitor of ADAM with antitumour effects, inhibiting ADAM10, ADAM17, MMP12 and MMP15.

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.

GSK040, a potent and highly selective inhibitor of BET BD2, exhibits a pIC50 of 8.3, demonstrating over 5000-fold selectivity against BET BD1 (pIC50=4.6). This compound is primarily utilized in oncology and immunology research [1].This compound is unstable in powder form and other related salt forms are recommended.

Ataquimast inhibits IL-5 secretion along with that of TNF-a, IL-4 and GM-CSF from human cells.

Benzyl cinnamate (Benzylcinnamoate) is a natural product isolated from various plant species,with anti-inflammatory activity.

beta-Escin is a natural mixture of triterpenoid saponins isolated from horse chestnut (Aesculus hippocastanum) seeds, can be used as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent.

(9α,13α,14α)-4-Hydroxy-3,7-dimethoxy-7,8-didehydromorphinan-6-one is a major mechanism of Sinomenine. Sinomenine is an alkaloid derived from the Chinese herb Sinomenium acutum (Thunb.) Rehd. et Wils. (9α,13α,14α)-4-Hydroxy-3,7-dimethoxy-7,8-didehydromorphinan-6-one exhibits anti-inflammation effects.

3-Epicorosolic acid has a potent inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) induction, it has potential anti-inflammatory activities as well as cancer chemopreventive activity.3-Epicorosolic acid shows both potent α-glucosidase and pro

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Chlorthenoxazine (Chlorethylbenzmethoxazone) has anti-inflammatory activity.

[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid (2-[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]ACETIC ACID) is an anti-inflammatory thiazole

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Bucolome (Paramidine) is a CYP2C9 inhibitor with uricosuric and anti-inflammatory activity.

CG347B is a selective inhibitor of HDAC6.

Sericoside, a triterpenoid compound, is obtained from Terminalia and exhibits potent anti-inflammatory properties. Additionally, sericoside displays robust lipolytic activity, thereby aiding in the reduction of skin wrinkles and improvement of skin texture.

ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.

Fendosal (HP-129) is a non-steroidal anti-inflammatory agent. It is 6.9 to 9.5 times more active than aspirin in the prophylactic and therapeutic adjuvant-induced polyarthritis models of chronic inflammation.

SpeB cysteine protease is a potent modifier capable of degrading proteins that are crucial for both host and bacterial immunology. It can break down streptolysin O (SLO) contained within extracellular vesicles.

Monophosphoryl Lipid A-12 (free acid) functions as a toll-like receptor 4 agonist, primarily utilized in immunology and vaccine research.

ZM522 is a CD73 inhibitor with an IC50 value of 0.56 μM. It effectively increases interferon-gamma (INF-γ) levels and enhances immune activity by modulating T cell activation. ZM522 holds potential for research in immunology and anti-cancer fields.

HPK1-IN-54 (Compound 16) is a potent inhibitor of HPK1 (hematopoietic progenitor kinase 1), enhancing T cell activation and proliferation by blocking HPK1 activity to exert antitumor effects. It has an IC50 of 2.67 nM for HPK1, showing excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 exhibits moderate in vivo clearance and reasonable oral exposure in both mice and rats. Additionally, in the CT26 mouse colon cancer model, HPK1-IN-54 demonstrates significant antitumor activity and shows a synergistic effect when combined with anti-PD-1 therapy. HPK1-IN-54 holds promise for research in the field of immunology.